NuVasive launches AttraX Scaffold biologic: 4 things to know

Written by Shayna Korol | June 12, 2018 | Print  |

NuVasive launched the AttraX Scaffold in the U.S. for use in the posterolateral spine to promote fusion.

Here are four things to know:

1. The AttraX Scaffold is an absorbent ceramic-collagen bone graft with surface technology designed to drive mesenchymal stem cell differentiation into osteoblasts without added growth factors.

2. Available in strips, blocks and morsels, the AttraX Scaffold complements NuVasive's currently marketed AttraX Putty product line to offer spine surgeons a suite of surface-optimized ceramic graft materials.

3. During preclinical testing in posterolateral fusion models, fusion rates with AttraX were equivalent to or better than autograft and faster than traditional ceramic grafts.

4. NuVasive biologics portfolio includes Osteocel in the cellular allograft category; Propel in the demineralized bone matrix category; and AttraX in the synthetic category.

More articles on biologics:

Spine biologics market to grow at CAGR of 4.09% through 2022

3 things to know about Lattice Biologics

8 key surgeon Q&As on biologics in orthopedics & spine

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months